Research Article

Clinical Characteristics of Turkish Women with Candida krusei Vaginitis and Antifungal Susceptibility of the C. krusei Isolates

Table 4

Antifungal susceptibility of 28 vaginal Candida  krusei isolates stratified according to clinical forms.

AntifungalsAcute VVC ( )Recurrent VVC ( )Control ( )

Amphotericin B ( g/mL)
 MIC range0.03–0.250.03–0.50.06–0.5
 MIC500.030.250.25
 MIC900.250.250.25
, ≥2  g/mL
(%)
5-Flucytosine ( g/mL)
 MIC range0.125–80.125–80.125–16
 MIC50228
 MIC908816
, ≥32  g/mL
(%)
Caspofungin ( g/mL)
 MIC range0.03–0.060.03–0.060.03–0.06
 MIC500.030.030.03
 MIC900.060.030.06
, ≥2  g/mL
(%)
Fluconazole ( g/mL)#
 MIC range16–12816–12816–128
 MIC501286432
 MIC90128128128
, ≥64  g/mL
(%)493
S-DD, 16–32  g/mL
(%)345
Itraconazole ( g/mL)
 MIC range0.125–160.125–160.125–8
 MIC500.250.250.125
 MIC90442
, ≥1  g/mL
(%)343
Voriconazole ( g/mL)
 MIC range0.125–80.125–160.25–8
 MIC5010.50.5
 MIC90442
, ≥4  g/mL
(%)221
Ketoconazole ( g/mL)
 MIC range0.125–80.25–80.25–8
 MIC500.2540.25
 MIC90288
, ≥16  g/mL
(%)
Econazole ( g/mL)
 MIC range0.5–10.125–20.5–1
 MIC50111
 MIC90121
, ND
(%)
Miconazole ( g/mL)
 MIC range0.25–0.50.06–10.25–0.5
 MIC500.250.250.25
 MIC900.510.5
, ≥4  g/mL
(%)
Sulconazole ( g/mL)
 MIC range1–40.06–41-2
 MIC50211
 MIC90442
, ND
(%)

VVC: vulvovaginal candidiasis; : resistance; S-DD: susceptible dose dependent; ND: not determined. #All isolates were declared resistant to fluconazole.